BioCryst Pharmaceuticals BCRX Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's effective income tax rate reconciliation at federal statutory income tax rate, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's effective income tax rate reconciliation at federal statutory income tax rate, amount?
- BioCryst Pharmaceuticals (BCRX) reported effective income tax rate reconciliation at federal statutory income tax rate, amount of $14.04M in Q4 2025.
- How has BioCryst Pharmaceuticals's effective income tax rate reconciliation at federal statutory income tax rate, amount changed year-over-year?
- BioCryst Pharmaceuticals's effective income tax rate reconciliation at federal statutory income tax rate, amount increased by 407.5% year-over-year, from -$4.57M to $14.04M.
- What is the long-term trend for BioCryst Pharmaceuticals's effective income tax rate reconciliation at federal statutory income tax rate, amount?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's effective income tax rate reconciliation at federal statutory income tax rate, amount has grown at a 10.1% compound annual growth rate (CAGR), from -$38.18M to $56.15M.
- What does effective income tax rate reconciliation at federal statutory income tax rate, amount mean?
- The dollar amount of income tax expense or benefit calculated by applying the federal statutory tax rate to the company's pre-tax income. This serves as the baseline figure for reconciling the actual effective tax rate against the standard corporate tax rate.